Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of “Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.86.

VOR has been the subject of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. Wedbush reissued an “outperform” rating and set a $7.00 price target on shares of Vor Biopharma in a report on Thursday, March 20th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Stifel Nicolaus lowered their price target on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, HC Wainwright dropped their price target on shares of Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a research note on Friday, March 21st.

Institutional Trading of Vor Biopharma

A number of large investors have recently bought and sold shares of the business. RA Capital Management L.P. lifted its holdings in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP acquired a new position in Vor Biopharma during the fourth quarter worth $707,000. Two Sigma Investments LP raised its holdings in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Northern Trust Corp lifted its stake in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares during the last quarter. Finally, Trustees of Columbia University in the City of New York bought a new stake in Vor Biopharma in the 4th quarter valued at $102,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Stock Down 4.4 %

Shares of VOR opened at $0.72 on Thursday. The stock’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.00. The firm has a market capitalization of $89.89 million, a price-to-earnings ratio of -0.44 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.